PFIZER LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,610 INR | +0.72% |
|
+2.36% | +7.98% |
| Sales 2024 | 21.93B 263M | Sales 2025 * | 23.76B 285M | Capitalization | 211B 2.53B |
|---|---|---|---|---|---|
| Net income 2024 | 5.51B 66.1M | Net income 2025 * | 6.26B 75.11M | EV / Sales 2024 | 8.75 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.87 x |
| P/E ratio 2024 |
34.8
x | P/E ratio 2025 * |
33.7
x | Employees | 1,702 |
| Yield 2024 * |
1.11% | Yield 2025 * |
0.99% | Free-Float | 33.1% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.72% | ||
| 1 week | +2.36% | ||
| 1 month | +8.28% | ||
| 3 months | +0.11% | ||
| 6 months | +12.85% | ||
| Current year | +7.98% |
1 week
4 468.00
4 636.95
1 month
4 175.054 680.00
Current year
3 950.005 000.00
1 year
3 724.105 000.00
3 years
3 408.006 175.00
5 years
2 792.256 175.00
10 years
1 207.006 175.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 23-04-02 | |
Pankaj Gupta
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 99-12-06 | |
| Director/Board Member | 74 | 12-05-20 | |
| Director/Board Member | 64 | 15-02-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 112 M€ | +4.61% | - | |
| 0.00% | 45 M€ | -.--% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 7 M€ | +5.36% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4,610 | +0.72% | 19,566 |
| 24-05-30 | 4,577 | -0.98% | 34,624 |
| 24-05-29 | 4,622 | +1.02% | 16,328 |
| 24-05-28 | 4,575 | +0.52% | 12,722 |
| 24-05-27 | 4,552 | +1.07% | 18,901 |
Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.98% | 2.53B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- PFIZER Stock
